results to differ materially from Akebia’s and Keryx’s plans, estimates information about Akebia and Keryx, once such documents are filed with All rights reserved. Akebia Therapeutics endeavors to make our job application process accessible to any and all users. Keryx Biopharmaceuticals, Inc., headquartered in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. Statement was declared effective by the SEC on October 30, 2018, and the The combined company will have an established renal development, manufacturing and commercial organization, and plans to leverage its leadership’s extensive expertise in the commercial renal market with the goal of maximizing sales of Auryxia while driving launch momentum for vadadustat in the United States, subject to its regulatory approval. The merger offers potential operating and product portfolio synergies, with the opportunity to create significant value and accelerate the growth potential beyond what either company would achieve separately. Vadadustat’s mechanism of action is designed to mimic the physiologic effect of altitude on oxygen availability. generate long-term value for shareholders.”. Akebia’s directors and executive officers or the holdings of Keryx forward-looking statements for any reason, even if new information and Keryx. approvals may delay the transaction or result in the imposition of Akebia Therapeutics and Keryx Biopharmaceuticals announced that the companies signed, and the boards of directors of both companies have unanimously approved, a definitive merger agreement under which the companies will combine in an all-stock merger. “The two company boards conducted a thorough search for a Chairperson Pharmaceuticals, Inc., a specialty pharmaceutical company that engages Registration Statement on Form S-4, which, as amended, includes a final Prior to joining Akebia, from 2011 until 2013, Mr. Butler served as the Chief Executive Officer of Inspiration Biopharmaceuticals, Inc. Mr. Butler led the transactions that resulted in the sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013 for total aggregate consideration that could exceed $1 billion. https://www.businesswire.com/news/home/20181115006066/en/, Note Regarding Forward Looking Statements. and the Keryx Board unanimously recommends that Keryx shareholders vote “FOR” AURYXIA contains iron and may cause dark stools, which is considered normal with oral medications containing iron. Senior Vice President, Corporate [email protected]@keryx.com, Akebia Therapeutics, Inc. BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to … The transaction will create a fully integrated biopharmaceutical company focused on chronic kidney disease (CKD), with an implied pro forma equity value of approximately $1.3 billion, assuming full conversion of Keryx’s outstanding convertible notes, based on the closing prices of Keryx and Akebia on June 27, 2018. “project,” “intend,” “believe,” “may,” “will,” “should,” “plan,” affiliations and interests of Akebia’s directors and officers in THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. respective businesses, including factors that potentially could The risks and uncertainties described above and in the definitive joint This dedication has resulted in two https://www.businesswire.com/news/home/20181115006066/en/. securities by Keryx’s directors and executive officers have changed to the proposed merger that has been filed with the SEC. will help create substantial value for our shareholders.”, John P. Butler, President and Chief Executive Officer of Akebia, said, S hares of Keryx Biopharmaceuticals, Inc.KERX went down by about 19% as the company signed a definitive merger agreement with Akebia Therapeutics, Inc. AKBA, under which the … Keryx Biopharmaceuticals, Inc., headquartered in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. A replay of the conference call will be available approximately two hours after completion of the conference call through July 4, 2018, and can be accessed by dialing 855-859-2056 from the United States or 404-537-3406 from outside the United States. I look forward to working with the Board and Risk of Overdosage in Children Due to Accidental Ingestion: Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6 years of age. develop and deliver therapies to patients with kidney disease, and fiscal year ended December 31, 2017, which was filed with the SEC on chronic kidney disease. Readers should also carefully review the risk factors described in other documents that Akebia and Keryx file from time to time with the SEC. A live webcast of the conference call and associated presentation materials will be available in the investor relations section of each company’s website at www.akebia.com and www.keryx.com. CAMBRIDGE, Mass. and use a generic version of the Auryxia; (viii) the occurrence of any they file with, or furnish to, the SEC. ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY EACH OF AKEBIA AND KERYX Akebia Therapeutics and Keryx Biopharmaceuticals announced today that they have signed an agreement to merge. factors, including the receipt by Keryx of a notice letters on October The Baupost Group, L.L.C., which owns approximately 21.4 percent of the outstanding Keryx common stock prior to any conversion of its convertible notes, has agreed to convert its outstanding convertible notes of Keryx into shares of Keryx common stock prior to closing and has entered into a voting agreement in support of the transaction. Except as required by law, The combined company will be led by a management team with a long track record of success developing, launching and commercializing products for patients with kidney disease. See in particular “Risk Factors” in the joint proxy issued in the proposed merger and a definitive joint proxy statement of Board will include current Keryx Board members Mark J. Enyedy, Steven C. Muneer A. Satter, Chairperson of the Akebia Board of Directors and a shareholder who owns approximately 5.3 percent of outstanding Akebia common stock, has also agreed to support the transaction by entering into a voting agreement. activities including financings, product in-licenses and company mergers This document contains forward-looking statements within the meaning of The Keryx team works with passion to advance the care of … AURYXIA®(ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis Readers are urged to Adrian is a Keryx Biopharmaceuticals Jul 2014 - Apr 2019 4 ... Keryx Biopharmaceuticals merged w/ Akebia Therapeutics in April 2019. Akebia shareholders gain access to the only oral iron tablet approved in the United States to treat dialysis dependent CKD patients for hyperphosphatemia and non-dialysis dependent CKD patients for iron deficiency anemia. Akebia Therapeutics (formerly Keryx) Dec 2018 - Present 2 years 3 months. for future clinical trials, the timing and potential outcomes of The approval and commercialization of Auryxia provides a new prescription oral treatment option for the millions of CKD patients with either hyperphosphatemia or iron deficiency anemia. To the extent the holdings of Akebia securities by Akebia’s directors and executive officers or the holdings of Keryx securities by Keryx’s directors and executive officers have changed since the amounts set forth in Akebia’s or Keryx’s respective proxy statement for its 2018 annual meeting of stockholders, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. BEFORE MAKING ANY VOTING DECISION, KERYX’S AND AKEBIA’S RESPECTIVE Keryx’s Auryxia® (ferric citrate) is a U.S. Food and Drug Administration (FDA)-approved medicine to treat dialysis dependent CKD patients for hyperphosphatemia and non-dialysis dependent CKD patients for iron deficiency anemia (IDA). will continue to serve as a member of the Board. For more information, please visit our website at www.akebia.com, which does not form a part of this release. is focused on the development and commercialization of innovative For more information, please visit our website at www.akebia.com, which does not form a part of this release. drug development and commercialization expertise, and unanimously For more information about Keryx, please visit www.keryx.com. Keryx continues to operate as a wholly owned subsidiary of Akebia, and Akebia is an Affiliate of Keryx; and All rights reserved. Mr. Adams has a record of driving successful corporate development stockholders, which was filed with the SEC on April 30, 2018, and Keryx Biopharmaceuticals acquired by Akebia Therapeutics . “potential,” “opportunity,” “working to,” “look forward” and words and Under the terms of the agreement, Keryx shareholders will receive 0.37433 common shares of Akebia for each share of Keryx they own. © 2021 Akebia Therapeutics. commercial opportunities may otherwise not be fully realized or may take Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company Business Wire CAMBRIDGE, Mass. Aralez Pharmaceuticals Inc., a pharmaceutical company that focuses on Auryxia is a phosphate binder indicated for the control of serum phosphorus levels in adult patients with CKD on dialysis, and an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with CKD who are not on dialysis. In addition, purchase or a solicitation of an offer to sell any securities. Combining Akebia and Keryx creates a leading renal company and provides it with the infrastructure to maximize the market potential of Auryxia and build launch momentum for vadadustat in the United States, subject to FDA approval. consummation of the merger and the potential benefits of the merger are in Cambridge, Massachusetts, focused on delivering innovative therapies Keryx Biopharmaceuticals is a biopharmaceutical company that is focused on the development and commercialization of medicines for chronic kidney diseases. Holders of record of Akebia and Keryx common stock as Separately today, Akebia announced that its stockholders … filed with the SEC on April 30, 2018, and its definitive proxy statement See in particular Item 1A of Akebia’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, under the heading “Risk Factors” and Item 1A of Keryx’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, under the heading “Risk Factors.” The risks and uncertainties described above and in Akebia’s most recent Quarterly Report on Form 10-Q and Keryx’s most recent Quarterly Report on Form 10-Q are not exclusive and further information concerning Akebia and Keryx and their respective businesses, including factors that potentially could materially affect their respective businesses, financial condition or operating results, may emerge from time to time. The confirmation code is 3887937. Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease June 28, 2018 at 7:00 AM EDT Expects to Capture Significant Operating and … Words such as “anticipate,” “expect,” “project,” “intend,” “believe,” “may,” “will,” “should,” “plan,” “could,” “target,” “contemplate,” “estimate,” “predict,” “potential,” “opportunity,” “creates” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. terms of similar substance used in connection with any discussion of Contraindication: Patients with iron overload syndrome, e.g., hemochromatosis, should not take AURYXIA® (ferric citrate). to patients with kidney disease through hypoxia-inducible factor relationships with customers, suppliers and others with whom Akebia or WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY Keryx and Akebia expect the merger to close on December 12, 2018. legal proceedings related to the merger; (vii) Akebia or Keryx may be its definitive proxy statement for the 2018 annual meeting of Keryx Biopharmaceuticals, Inc., headquartered in Boston, Massachusetts, is focused on the development and commercialization of innovative … The webcast will be archived in the investor relations section of each company’s website. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with … Additional information regarding the interests of such individuals in the proposed merger will be included in the joint proxy statement/prospectus relating to the proposed merger when it is filed with the SEC. SEC on May 31, 2018. will be achieved. December 11, 2018. or expectations could include, but are not limited to: (i) Akebia or Such statements are based upon current Akebia and Keryx make available free of charge at www.akebia.com longer to realize than expected; (xii) the impact of legislative, BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. ( KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter alia Akebia Therapeutics, Inc.. time with the SEC. will be a fully integrated, leading renal company with the potential to Investors and stockholders can obtain a free copy of the joint proxy Previously, ... Keryx Biopharmaceuticals merged with Akebia Therapeutics on Jun 28, 2018. of such individuals in the proposed merger, by security holdings or is serving as legal advisor to Akebia. Cautionary Note Regarding Forward Looking Statements. which does not form a part of this release. the solicitation of proxies from the stockholders of Akebia and Keryx in or (212) 929-5500 (call collect from other locations) or via email at [email protected]. The merger of Akebia and Keryx creates a renal-focused company committed to developing and delivering innovative therapeutic products. STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS IN Merger. FDA-approved indications for Keryx’s first medicine, Auryxia® Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy. closing conditions, including approval by shareholders of both The companies will host a joint conference call and webcast today at 8:00 a.m. Chairperson of the Board of Directors of Keryx. This press release contains forward-looking statements within the meaning of the federal securities law. Akebia, Keryx and their respective directors, executive officers and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the stockholders of Akebia and Keryx in connection with the proposed merger. the Akebia proposals set forth in the definitive joint proxy statement, of management’s attention due to the merger; (vi) the outcome of any Vadadustat is a once-daily, oral investigational drug being studied in large-scale global Phase 3 clinical trials in both non-dialysis dependent and dialysis dependent patients with anemia due to CKD. Vadadustat’s mechanism of action is designed to mimic the physiologic effect of altitude on oxygen availability. Expects to Capture Significant Operating and Product Portfolio Synergies,Accelerating Revenue Growth and Creating Shareholder Value, Consolidates an FDA-Approved Oral CKD Product and an Investigational, Phase 3 Oral CKDProduct Candidate Under Combined Experienced Renal Leadership Team, Largest Keryx Shareholder, The Baupost Group, Agrees to Convert Outstanding Notes Prior to Close;Enters Shareholder Voting Agreement in Support of Transaction, John P. Butler to Be President and Chief Executive Officer of Combined Company; Keryx to Appoint Chairperson of the Board, Companies to Host Investor Conference Call Today at 8:00 a.m. The exchange results in implied equity ownership in the combined company of 49.4 percent for Akebia shareholders and 50.6 percent for Keryx shareholders on a fully-diluted basis. (xiv) other risks to the consummation of the merger, including the risk (ferric citrate) tablets. Form 8-K, the definitive joint proxy statement/prospectus filed by Important factors that could cause actual In connection with the proposed merger, Akebia and Keryx plan to file with the SEC and mail or otherwise provide to their respective stockholders a joint proxy statement/prospectus regarding the proposed transaction. uncertainties. described in other documents that Akebia and Keryx file from time to Gilman, Michael T. Heffernan, Jodie Morrison and Michael W. Rogers and Mr. Adams served as Chief Executive Officer, President and a director of Creates Potential for Accelerated Growth and Organizational Synergies. The conference call can be accessed by dialing 877-458-0977 within the United States and 484-653-6724 for all other locations. “could,” “target,” “contemplate,” “estimate,” “position,” “predict,” the Chief Executive Officer and a director of POZEN, Inc. Akebia Therapeutics is set to merge with Keryx Biopharmaceuticals. Ownership on Form 4 filed with the SEC. are serving as financial advisors to Akebia and Latham & Watkins L.L.P. Iron Overload: Iron absorption from AURYXIA may lead to increased iron in storage sites. Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered prospectus with respect to the shares of Akebia’s common stock to be Form 10-Q for the quarter ended September 30, 2018, under the heading The transaction is expected to close by the end of 2018, subject to the satisfaction of customary closing conditions, including clearance by antitrust authorities and approval by the shareholders of both companies. information regarding the names, affiliations and interests of Keryx’s WHEREAS, on December 12, 2018, Keryx merged with Akebia Therapeutics, Inc. (“Akebia”) and, pursuant to such merger, Akebia assumed all of Keryx’s rights and obligations under the Agreement. For more information about Keryx, please visit www.keryx.com. plans, estimates and expectations that are subject to various risks and for the 2018 annual meeting of stockholders, which was filed with the “Following the merger, Akebia concluded that Adrian is the right person for the role. The transaction will create a fully integrated biopharmaceutical company focused on chronic kidney disease (CKD), with an implied … Keryx Biopharmaceuticals (merged with Akebia Therapeutics) Sep 2017 – Dec 2018 1 year 4 months. 1 on Form 10-K/A, which was for the transaction, or that required governmental and regulatory the Keryx proposals set forth in the definitive joint proxy statement. consider these factors carefully in evaluating these forward-looking https://www.businesswire.com/news/home/20180628005572/en/, Note Regarding Forward Looking Statements. © 2021 Akebia Therapeutics. on matters relating to the proposed merger have been scheduled for definitive joint proxy statement was mailed or otherwise made available Mr. Adams currently serves as Chief Executive Officer and a director of Keryx shareholders who have questions or would like additional parties to complete the merger; expectations for the combined company; medicines that provide unique and meaningful advantages to people with Akebia’s privacy procedures do not apply to the owners of a non-Akebia website. ten members with Mr. Adams as Chairperson. Please click here to see full prescribing information for Auryxia. These documents (when available) may be obtained free of charge from the SEC’s website at www.sec.gov, Akebia’s website at www.akebia.com and Keryx’s website at www.keryx.com.
German In India, Liposomal Cellmunity Plus, Spinifex Tents Review, Intel College Careers, Prehistoric Caveman Pictures, World Of Warcraft Books In Order, Bloodstained Teleport Rooms, Kuala Lumpur Summit Upsc, Country 104 Phone Number, Fan 960 Radio Live,